Session 1B. - Hall 4. 15h30 16h00 Refreshments, exhibition and posters - Hall 5 16h00 17h30 Session 2: Open Session. - Hall 4

Size: px
Start display at page:

Download "Session 1B. - Hall 4. 15h30 16h00 Refreshments, exhibition and posters - Hall 5 16h00 17h30 Session 2: Open Session. - Hall 4"

Transcription

1 CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding (Julia Turner) - Previously on PrEP, now pregnant. What to do? (Tshidi Sebitloane) - Teen adherence (Juliet Houghton) - Breast abnormalities in adolescents receiving ART (Jackie Dunlop) Chair: Moherndran Archary 15h30 16h00 Refreshments, exhibition and posters 16h00 17h30 Session 2: Open Session Debate: Undetectable = Untransmittable - Yes (Annemarie Wensing) - No (Graeme Meintjes) Chair: Yunus Moosa and Moeketsi Mathe 17h40 19h00 Session 3: Opening Plenary Welcome (Moeketsi Mathe) Official conference opening (Desmond Martin) Mechanism of resistance (Douglas Richman) HIV drug resistance: are we about to win the war? (John Mellors) Chair: Annemarie Wensing Session 1B Adult cases (Michelle Venter, Kim Roberg, Eric Hefer) - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion (Gary Maartens, Yunus Moosa) Chair: Jeremy Nel Session 1C - Skills building - Nurse cases - Cases primary healthcare, rural doctors (Ndiviwe Mphothulo, Jenny Nash) - Cases nurses (Talitha Crowley, Gloria Mthombeni) - Panel discussion: Integration; Re-starting (Ndiviwe Mphothulo, Talitha Crowley, Gloria Mthombeni, Jenny Nash) Chair: Gloria Maimela Southern African HIV Clinicians Society Conference 2018 programme subject to change 2 P a g e

2 19h00 21h00 Opening Cocktail Function THURSDAY, 25 OCTOBER h30 08h15 Session 4A Stock outs and medicine availability - Stop Stockouts Project - Essential medicines to add to the formulary (Tinne Gils) - Not deaf or dead! The seven-year journey of bedaquiline as a third choice for all South Africans with MDR-TB, as told by one fortunate MDR-TB survivor. (Arne von Delft) Chair: Anele Yawa 08h20 10h15 Session 5: Plenary Session How are we doing with HIV self-screening? (Francois Venter) - How are we doing with Universal test and treat? - How are we doing with viral suppression? (Sergio Carmona) Chair: 10h15 10h30 Refreshments, exhibition and posters 10h30 12h00 Session 6A Session 6B Pharmacovigilance and registers - Pharmacovigilance (Karen Cohen) - Pregnancy register (Mukesh Dheda) - Registers and centralised reporting (Ruth Lancaster) Chair: Gary Maartens - Skills building session Infant testing - Swallowing tablets (Melanie Collins) - Optimising formulations (Carol Ruffell) - The latest on infant testing, and how to access (Gayle Sherman) Session 4B Ethics and research - The informed consent process (Lucy Allais and Mary Carman) Session 6C Ethics and the Law - Whistle-blowing in the health-sector (Mark Heywood) - Mandatory testing (Wayne Ncube) - Ethics on how health budgets are split (Marije Versteeg-Mojanaga) - Q&A Chair: Lucy Allais Southern African HIV Clinicians Society Conference 2018 programme subject to change 3 P a g e

3 - Switching in children (Helena Rabie) - Weight and age (Helena Rabie) Chair: James Nuttall 12h00 13h30 Lunch, exhibition and posters (Poster track: Paediatric and Adolescents) Satellite Session 7 GlaxoSmithKline session 13h30 15h00 Session 8A Cancer treatment models - Kaposi Sarcoma (Zainab Mohamed) - Lymphoma (Zainab Mohamed) - Priorities for cervical cancer prevention among HIV-infected women (Masangu Mulongo) - Update on cancer treatment (Adam Nosworthy) Chair: Moosa Patel 15h00 15h30 Refreshments, exhibition and posters Hall 5 15h30 17h00 Session 9A An update on - NRTIs (Yunus Moosa) - NNRTIs (Michelle Moorhouse) - Protease Inhibitors (Sipho Dlamini) Session 8B Resistance - Viral resistance first-line and second-line (Graeme Meintjes) - At which detectable viral load should we switch? (Lucas Hermans) - Third-line treatment. Feedback on outcome of patients on national third-line regimen (Michelle Moorhouse) - Transmitted drug resistance: surveillance, implications, future (Cloete van Vuuren) Chair: Theresa Rossouw Session 9B What s coming / What s missing in paediatrics - Integrase inhibitors (James Nuttall) - Protease Inhibitors (Leon Levin) Session 8C Prevention - Non-biomedical approaches (Sue Goldstein) - Condoms (Mags Beksinska) - Update on trials of vaccines and monoclonals in SA; how PrEP could augment these approaches (Fatima Laher) - Voluntary medical male circumcision (Limakatso Lebina) - Treatment as prevention (Francois Venter) Chair: Fatima Laher Session 9C Modelling and scale-up - What are the numbers telling us - How the epidemic informs resource planning Southern African HIV Clinicians Society Conference 2018 programme subject to change 4 P a g e

4 - Integrase inhibitors (Francois Venter) - Drug-drug interaction (Gary Maartens) Chair: Karen Cohen 17h10 18h40 Session 10A Skills building session Resistance - Third-line (Leon Levin) - Paediatric third-line (Moherndran Archary) - Stanford database - how to interpret resistance test results (Robert Shafer) Chair: Cloete van Vuuren - Drug interactions (Moherndran Archary) Chair: Nosisa Sipambo Session 10B - Skills building session Counselling - How to deliver HIV risk reduction counselling in 2018 (Janan Dietrich) - Integrating HIV prevention with other services (Natasha Davies) - How to tell a teenager they have HIV: A practical approach (Julia Turner) - Uptake and yield of a 24/7 HIV testing service across four Eastern Cape hospital Emergency departments (Dave Stead) Chair: Pierre Brouard 18h50 20h20 Session 11: Debate (Open Session) Hall 4 Implications of scarcer resources for 90:90:90 (Gloria Maimela) - Panel: Elliot Raizes, Annemarie Wensing, Jean Nachega, Francois Venter Chair: FRIDAY, 26 OCTOBER h30 08h15 Southern African HIV Clinicians Society AGM 08h30 10h00 Session 12: Plenary Our current understanding of antibodies (Nono Mhkize) Cost effectiveness of TLD versus TEE (Gesine Meyer-Rath) Chair: Richard Borain Session 10C National Health Insurance - Keynote: Mark Heywood Southern African HIV Clinicians Society Conference 2018 programme subject to change 5 P a g e

5 Why do we need cure (John Mellors) How do you measure cure (Monique Nijhuis) Management of patients with advanced HIV (Graeme Meintjes) 10h00 10h30 Refreshments, exhibition and posters 10h30 12h00 Session 13A Session 13B Opportunistic infections - An approach to intracranial mass lesions in HIV patients (Dave Stead) - Pneumocystis pneumonia (Michelle Wong) - Endemic mycoses in HIV patients (Jade Mogambery) - An approach to chronic diarrhoea (Sipho Dlamini) Chair: Colin Menezes HIV and TB in children and adults - Paediatric TB diagnosis and management (Ashendri Pillay) - TB in children and HIV-TB coinfection (Fiona Kritzinger) - TB in adults and HIV-TB coinfection (Ndiviwe Mphothulo) - TB and HIV co-infection including IRIS (Richard Lessells) Chair: Kogieleum Naidoo 12h00 13h30 Lunch, exhibition and posters (Poster tracks: Antiretroviral Treatment; Primary Health Care and Nursing; Basic Science; Opportunistic Infections and Malignancies; HIV Treatment Failure and Drug Resistance) 13h30 15h00 Session 15: Plenary Botswana Dolutegravir experience (Ava Avalos) Could good point-of-care testing revolutionise issues in the region? (Peter Manyike) Balancing politicians, ministries of health, communities and donors (Paula Munderi) Chair: 15h00 15h30 Refreshments, exhibition and posters 15h30 17h00 Session 16A Session 16B Session 13C Key populations and mobile populations - Injecting drug users in the region (Andrew Scheibe) - Sex workers including satellite clinics; peer support (Naomi Hill) - Engaging in care (Naomi Hill) - Testing in taxi ranks (Thandeka Khoza) Chair: Kholi Buthelezi Satellite Session 14 GILEAD session Session 16C Southern African HIV Clinicians Society Conference 2018 programme subject to change 6 P a g e

6 Skills building Clinical skills building (Henry Sunpath, Yunus Moosa) Should the private sector be treating TB? Yes No Chair: Kogieleum Naidoo Update on PMTCT - Where are we with PMTCT, including epidemiology (Landon Myer) - Transmission of HIV in breastfeeding (Ameena Goga) - Pregnant women on ART programmatic issues (Coceka Mnyani) - Contraception, clinical issues, MPTs and new technologies (Helen Rees) Chair: Tshidi Sebitloane 17h10 18h40 Session 17 Hall 4 Dolutegravir in pregnancy - Overview (Landon Myer) - DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy (Catherine Orrell) - Dolutegravir rollout (Steven Smith) - Debate: Treatment for children Dolutegravir versus Raltegravir Chair: Landon Myer 19h00 22h30 Celebratory Dinner (RSVP only additional fee applies) SATURDAY, 27 OCTOBER h30 08h15 Session 18 Auditorium Meet the Professor / Clinician How did I start my academic / research career? (Dave Spencer; Francois Venter; Michelle Moorhouse; Yunus Moosa; Gary Maartens) 08h30 10h00 Session 19: Plenary Vaccinations - Overview (Benjamin Kagina) Southern African HIV Clinicians Society Conference 2018 programme subject to change 7 P a g e

7 - Influenza vaccines (Shabir Madhi) - HIV vaccines - SAHCS vaccination guidelines (Sipho Dlamini) Chair: Rudzani Muloiwa 10h00 10h30 Refreshments, exhibition and posters 10h30 12h00 Session 20A Session 20B Noncommunicable diseases - Inflammation (Dave Spencer) - Hypertension - Obesity (Denasha Reddy) - Mental health (John Joska) - Injection drug use, HIV and hepatitis (Moeketsi Mathe) Chair: Marlin McKay Ethics and technology - Electronic medical records (Sandile Mhlongo) - Digital database and the PoPI act (Siraaj Adams) - Ethico-legal framework for biobank research in SA (Safia Mahomed) - EMGuidance (Mohammed Dalwai) Chair: Funeka Bango 12h00 13h30 Lunch, exhibition and posters (Poster tracks: Operations Research; Prevention; TB; Women s Health; Key Populations; Non-Communicable Diseases; Clinical Skills Building) 13h30 15h00 Session 22A - Advanced HIV Management - Care of aging patients (Marlin McKay) - Cryptococcal meningitis (Charlotte Sriruttan) - Palliative care (Dave Spencer) Chair: Dave Spencer Session 22B Treatment optimisation - (Polly Clayden, Francois Venter, Gary Maartens, Michelle Moorhouse, Graeme Meintjes, Landon Myer) Chair: Polly Clayden Session 20C Sexually transmitted infections - Strategies to achieve STI control in South Africa (Remco Peters) - Hepatitis C (Andrew Scheibe) - Update on vaginal microbiome and HIV - In context of PrEP (Danielle Travill) - Management of STIs in HIV+ population case-based (Ranmini Kuluratne) Chair: Helen Rees Satellite Session 21 Johnson & Johnson session - Optimising treatment for life-long management of HIV Session 22C Best abstracts session - Constructing TB cascades to inform TB programme improvement (Kate Rees) - HIV drug resistance profiles in patients failing integrase strand transfer inhibitors in the South African public sector (Kim Steegen) Southern African HIV Clinicians Society Conference 2018 programme subject to change 8 P a g e

8 15h10 16h40 Session 23A Skills building Guidelines: all new (Sipho Dlamini, James Nuttall, Dave Spencer, Natasha Davies, Michelle Moorhouse) Session 23B Adherence - Adherence (Catherine Orrell) - Adherence clubs (MSF) - Continued Use of PrEP among Sex Workers in Six Sites in South Africa (Cara O Connor) - Linking paediatric, adolescent and adult patients to care through the implementation of clinic navigators in high volume facilities (Chantal Smith) - Perceptions of HIV-Self Screening (Nthabiseng Koloane) - Viral load suppression among pregnant women presenting on ART in antenatal care; Chiredzi District Zimbabwe (Talent Maphosa) - Evaluation of the new Option B+ PMTCT program for HIV at hospital facilities: case study at the Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa (Melanie Bisnauth) - Triple-NRTI regimens while on TB treatment in a resource constrained setting a paediatric cohort analysis (Jennifer Minnaar) - Youth Care Clubs: Optimising clinic time, fostering peer support, improving adherence (Moira Beery) Session 23C - Quality Improvement - The Aurum Institute (Lauren de Kock, Winnet Chiningwenya) Southern African HIV Clinicians Society Conference 2018 programme subject to change 9 P a g e

9 - Virological monitoring how it relates to adherence (Henry Sunpath) Chair: Maria Sibanyoni 16h50 18h15 Session 24: Closing Plenary Big challenges in public health Big challenges in TB drug resistance (Richard Lessells) Big challenges in introducing and scaling up new prevention technologies (Helen Rees) Chair: Gary Maartens 18h15 18h20 Conference closing Moeketsi Mathe Southern African HIV Clinicians Society Conference 2018 programme subject to change 10 P a g e

15h30 16h00. 16h00 17h30. 17h40 19h Southern African HIV Clinicians Society Conference 2018 programme subject to change 2 P a g e

15h30 16h00. 16h00 17h30. 17h40 19h Southern African HIV Clinicians Society Conference 2018 programme subject to change 2 P a g e CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding (Julia Turner) - Previously

More information

Southern African HIV Clinicians Society Conference 2018 programme subject to change 2 P a g e

Southern African HIV Clinicians Society Conference 2018 programme subject to change 2 P a g e CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding - Previously on PrEP, now

More information

Session 1B - Auditorium Adult cases - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion

Session 1B - Auditorium Adult cases - Adherence - Mental health - STIs - Opportunistic Infections - TB - Drug Interactions Panel discussion CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding - Previously on PrEP, now

More information

Session 1B. - Hall 4. - Hall 4

Session 1B. - Hall 4. - Hall 4 CONFERENCE PROGRAMME WEDNESDAY, 24 OCTOBER 2018 08h00 18h00 Registration OFFICIAL MEETING COMMENCES 14h00 15h30 Session 1A Adolescent cases - Teen pregnancy and breast feeding (Julia Turner) - Previously

More information

versus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects

versus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects PRE-CONFERENCE WORKSHOPS WEDNESDAY, 24 OCTOBER 2018 10h00 14h00 Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop Pre-Conference Workshop ITREMA trial feedback PrEP for the private

More information

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme WEDNESDAY, 24 SEPTEMBER 2014 SA HIV Clinicians Society Conference 2014 - Excelling in Clinical Care : Programme 12h00-19h00 REGISTRATION 10h00-14h00 PRE-CONFERENCE WORKSHOP Metropolitan Health sponsored

More information

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme WEDNESDAY, 24 SEPTEMBER 2014 SA HIV Clinicians Society Conference 2014 - Excelling in Clinical Care : Programme 12h00-19h00 REGISTRATION 10h00-14h00 PRE-CONFERENCE WORKSHOP Metropolitan Health sponsored

More information

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013 Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will

More information

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme

SA HIV Clinicians Society Conference Excelling in Clinical Care : Programme SA HIV Clinicians Society Conference 2014 - Excelling in Clinical Care : Programme WEDNESDAY, 24 SEPTEMBER 2014 08h00-19h00 10h00-13h55 12h30 13h55 REGISTRATION PRE-CONFERENCE WORKSHOP Metropolitan Health

More information

World Health Organization. A Sustainable Health Sector

World Health Organization. A Sustainable Health Sector World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL

More information

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84 Clinical guidelines across THE CONTINuUM OF CARE: LINKING PEOPLE DIAGNOSEd WiTH hiv infection to hiv care and treatment 06 6.1 Introduction 84 6.2 Good practices for linkage to care 84 6.3 General care

More information

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness

More information

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile

More information

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall 2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University

More information

TasP and PrEP- Wishful thinking in the developing world?

TasP and PrEP- Wishful thinking in the developing world? TasP and PrEP- Wishful thinking in the developing world? Professor Helen Rees Executive Director, WRHI, Wits Reproductive Health and HIV Institute & Ad Hominem Professor, Department of Ob/Gyn, University

More information

Prioritized research questions for adolescent HIV testing, treatment and service delivery

Prioritized research questions for adolescent HIV testing, treatment and service delivery Prioritized research questions for adolescent HIV testing, treatment and service delivery The World Health Organization (WHO) and the Collaborative Initiative for Paediatric HIV Education and Research

More information

South Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018

South Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018 South Africa s National HIV Programme Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH 23 October 2018 Overview The HIV and AIDS sub-programme at NDOH is responsible for: policy formulation, coordination,

More information

PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE

PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE CHAPTER 2 PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE 2.1 INTRODUCTION Achieving quality integrated HIV services at your health centre is dependant on good planning and management. This chapter

More information

WHO WHO AIDS 2018 JOIN US AT

WHO WHO AIDS 2018 JOIN US AT WHO AIDS 2018 JOIN US AT WHO at AIDS 2018 TEDROS GHEBREYESUS Director-General, WHO ZSUZSANNA JAKAB WHO Regional Director for Europe REN MINGHUI WHO Assistant Director-General for Communicable Diseases

More information

Impact of South Africa s PMTCT Programs on Perinatal HIV Transmission: Results of the 1st Year Implementing 2010 WHO Recommended Guidelines

Impact of South Africa s PMTCT Programs on Perinatal HIV Transmission: Results of the 1st Year Implementing 2010 WHO Recommended Guidelines Impact of South Africa s PMTCT Programs on Perinatal HIV Transmission: Results of the 1st Year Implementing 2010 WHO Recommended Guidelines Thu-Ha Dinh, MD., MS., US CDC/GAP Ameena Goga, MD., MS., MRC/HSRU,

More information

Immunisation in people living with HIV. Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN

Immunisation in people living with HIV. Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN Immunisation in people living with HIV Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN Calculating immunisation s return on investment In Gavi-supported countries, 2011 2020 48x (full income

More information

TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES

TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment

More information

Program to control HIV/AIDS

Program to control HIV/AIDS 90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,

More information

Future trends of drug resistance and prospects of antiviral therapy. Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018

Future trends of drug resistance and prospects of antiviral therapy. Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018 Future trends of drug resistance and prospects of antiviral therapy Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018 The principles of HIV drug resistance are well established

More information

Programme. Co-Chairs. Take the conversation further online follow AIDS #AIDS2016

Programme. Co-Chairs. Take the conversation further online follow AIDS #AIDS2016 EVIDENCE TOACTION This session will highlight the essential role that collaborative research plays in improving public sector policies and services for HIV treatment and prevention. Across southern Africa

More information

GLOBAL AIDS MONITORING REPORT

GLOBAL AIDS MONITORING REPORT KINGDOM OF SAUDI ARABIA MINISTRY OF HEALTH GLOBAL AIDS MONITORING REPORT COUNTRY PROGRESS REPORT 2017 KINGDOM OF SAUDI ARABIA Submission date: March 29, 2018 1 Overview The Global AIDS Monitoring 2017

More information

ITREMA is a collaborative project between several universities in The Netherlands and South Africa and Ndlovu Care Group.

ITREMA is a collaborative project between several universities in The Netherlands and South Africa and Ndlovu Care Group. ITREMA is a collaborative project between several universities in The Netherlands and South Africa and Ndlovu Care Group. Objective: To do research into the best way to use viral load testing to ensure

More information

Genotypic Resistance Testing in Routine Care in South Africa:

Genotypic Resistance Testing in Routine Care in South Africa: Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts

More information

How are we doing with Universal Test and Treat?

How are we doing with Universal Test and Treat? How are we doing with Universal Test and Treat? Francois Venter October 2018 Thanks DoH, WHO, PEPFAR, CHAI, UCT, Joep Lange Institute, Celicia Serenata, Steve Smith, David Allen Optimising ART Consortia

More information

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of

More information

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis

More information

Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study.

Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study. Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study. K. Reichmuth 1, J. Nuttall, H. Rabie, B. Eley, H. Moultrie,

More information

TB and HIV co-infection including IRIS

TB and HIV co-infection including IRIS TB and HIV co-infection including IRIS Richard Lessells SAHCS Conference 2018 Clinical scenario 1 36-year-old male Presents with cough, fever & weight loss HIV test positive (new diagnosis) Sputum Xpert

More information

ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS

ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS Dr T Chidarikire HIV PREVENTION STRATEGIES 13 JUNE 2017 1 Purpose To share the Health Sector HIV Prevention Strategy with

More information

The elimination equation: understanding the path to an AIDS-free generation

The elimination equation: understanding the path to an AIDS-free generation The elimination equation: understanding the path to an AIDS-free generation James McIntyre Anova Health Institute & School of Public Health & Family Medicine, University of Cape Town Elimination of perinatal

More information

Towards universal access

Towards universal access Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress

More information

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation

More information

Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya

Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya KPA 2018 24-04-2018 Dr. Margaret Wainaina- Wafula Outline Introduction Evaluation of a child living with HIV. Standard

More information

IFMSA Policy Statement Ending AIDS by 2030

IFMSA Policy Statement Ending AIDS by 2030 IFMSA Policy Statement Ending AIDS by 2030 Proposed by IFMSA Team of Officials Puebla, Mexico, August 2016 Summary IFMSA currently acknowledges the HIV epidemic as a major threat, which needs to be tackled

More information

7 th FIDSSA CONFERENCE 2017 Programme as at 11 May 2017 PROVISIONAL ACADEMIC PROGRAMME

7 th FIDSSA CONFERENCE 2017 Programme as at 11 May 2017 PROVISIONAL ACADEMIC PROGRAMME THURSDAY 9 NOVEMBER 15h00 17h00 Conference Registration FIDSSA Official Opening Ceremony 17h00 17h15 Welcome & Opening - Marc Mendelson (FIDSSA President) PLENARY SESSION 1: Emerging and Re-Emerging Infectious

More information

SA HIV Clinicians Society Adult ART guidelines

SA HIV Clinicians Society Adult ART guidelines SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with

More information

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical

More information

Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff

Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme- 20171031[2].tiff Mo Archary King Edward VIII Hospital / UKZN Paediatric Infectious Diseases Unit Overview State

More information

Catherine Martin. Abstract #157. SA AIDS Conference. June 2017

Catherine Martin. Abstract #157. SA AIDS Conference. June 2017 Catherine Martin SA AIDS Conference Integrated sexual and reproductive health services as an entry point to HIV testing, prevention and care for adolescent girls and young women in Johannesburg, South

More information

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory

More information

PEPFAR Priorities & HIV Drug Resistance: Where are we heading and what has us worried

PEPFAR Priorities & HIV Drug Resistance: Where are we heading and what has us worried PEPFAR Priorities & HIV Drug Resistance: Where are we heading and what has us worried Elliot Raizes, MD Division of Global HIV & TB CDC Center for Global Health May 3, 2016 Center for Global Health Division

More information

The CQUIN Learning Network. Adolescents Living with HIV: Legal framework for testing, treatment, and transition, Challenges and Priorities: Uganda

The CQUIN Learning Network. Adolescents Living with HIV: Legal framework for testing, treatment, and transition, Challenges and Priorities: Uganda The CQUIN Learning Network Adolescents Living with HIV: Legal framework for testing, treatment, and transition, Challenges and Priorities: Uganda Teddy N. Chimulwa STD/AIDS Control Program, Ministry of

More information

WHO HIV Drug Resistance Prevention and Assessment Strategy. Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team

WHO HIV Drug Resistance Prevention and Assessment Strategy. Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team WHO HIV Drug Resistance Prevention and Assessment Strategy Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team Eastern & Southern African Countries (ESA) 2 The HIV epidemic

More information

Differentiated Care Improving Engagement and Retention in HIV Care. Meg Doherty, MD PhD MPH World Health Organization

Differentiated Care Improving Engagement and Retention in HIV Care. Meg Doherty, MD PhD MPH World Health Organization Differentiated Care Improving Engagement and Retention in HIV Care Meg Doherty, MD PhD MPH World Health Organization Why differentiated care and how can it facilitate epidemic control Effects on linkage,

More information

Can we make first line ART better?

Can we make first line ART better? Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics

More information

AIDS 2010 XVIII International AIDS Conference Vienna July 2010

AIDS 2010 XVIII International AIDS Conference Vienna July 2010 Official provider of online scientific news AIDS 2010 AIDS 2010 XVIII International AIDS Conference Vienna 18-23 July 2010 Friday 23 July 2010 New drug rilpivirine does well in trials Rilpivirine (TMC278)

More information

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT) Objectives Prevention of Mother-to-Child Transmission (PMTCT) Teen Club Community Partners Training Programme By the end of the session participants will be able to: 1. Identify factors affecting the transmission

More information

Starting with the end in mind: Experience of transitioning to sustainable services (KZN)

Starting with the end in mind: Experience of transitioning to sustainable services (KZN) Starting with the end in mind: Experience of transitioning to sustainable services (KZN) Hilton Humphries Adolescent Programme Director MA (Research Psychology), PhD candidate Position: Behavioural Scientist

More information

HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012

HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012 HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012 Number of Cases Note: In this surveillance report, HIV cases include persons reported with HIV infection (non-aids), advanced HIV (non-aids) and AIDS within a

More information

Breast Abnormalities in Adolescents receiving Antiretroviral Therapy. Dr Jackie Dunlop 24 October 2018

Breast Abnormalities in Adolescents receiving Antiretroviral Therapy. Dr Jackie Dunlop 24 October 2018 Breast Abnormalities in Adolescents receiving Antiretroviral Therapy Dr Jackie Dunlop 24 October 2018 Introduction Gynaecomastia related to ART in adult males is well documented Few studies have described

More information

INTRODUCTION AND GUIDING PRINCIPLES

INTRODUCTION AND GUIDING PRINCIPLES CHAPTER 1 INTRODUCTION AND GUIDING PRINCIPLES The Operations Manual is intended for use in countries with high HIV prevalence and provides operational guidance on delivering HIV services at health centres.

More information

South African goals and national policy

South African goals and national policy Connecting the dots for EMTCT A Decade of PMTCT South Africa has been one of the counties in sub-saharan Africa to be hard hit by the HIV virus. Despite this, the country did not implement its PMTCT programme

More information

THE ROLE OF THE SOUTH AFRICAN SOCIETY OF PHYSIOTHERAPY IN SUPPORT OF THE NATIONAL HIV & AIDS AND STI STRATEGIC PLAN FOR SOUTH AFRICA

THE ROLE OF THE SOUTH AFRICAN SOCIETY OF PHYSIOTHERAPY IN SUPPORT OF THE NATIONAL HIV & AIDS AND STI STRATEGIC PLAN FOR SOUTH AFRICA THE ROLE OF THE SOUTH AFRICAN SOCIETY OF PHYSIOTHERAPY IN SUPPORT OF THE NATIONAL HIV & AIDS AND STI STRATEGIC PLAN FOR SOUTH AFRICA 2012-2016 South African Society of Physiotherapy P.O. Box 752378 Gardenview

More information

HIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016

HIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016 HIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016 1 Thus the HIV DR needs to focus on prevention and then diagnostic capacity to 1 st provide VL monitoring for early &

More information

Evolving HIV Treatment Paradigms What we need to know

Evolving HIV Treatment Paradigms What we need to know Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines

More information

Uganda. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)

Uganda. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015) WHO/CDS/HIV/18.50 Demographic and socioeconomic data Uganda HIV Country Pro le: 2017 42.9 million Total population (2017) 1 820 US$ GNI per capita, PPP (2017) 343 Maternal mortality per 100 000 live births

More information

BUDGET AND RESOURCE ALLOCATION MATRIX

BUDGET AND RESOURCE ALLOCATION MATRIX Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes

More information

Cote D'Ivoire. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)

Cote D'Ivoire. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015) WHO/CDS/HIV/18.50 Demographic and socioeconomic data Cote D'Ivoire HIV Country Pro le: 2017 24.3 million Total population (2017) 3 820 US$ GNI per capita, PPP (2017) 645 Maternal mortality per 100 000

More information

INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION

INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES WHO guidelines [EXECUTIVE SUMMARY] NDoH PrEP policy [FULL] NDoH PrEP guidelines [FULL] FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION

More information

EACS HIV Summer School PRELIMINARY PROGRAMME

EACS HIV Summer School PRELIMINARY PROGRAMME EACS HIV Summer School Thursday, August 30, 2018 Monday, September 3, 2018 Montpellier, France This 5-day residential course is designed for clinicians experienced in HIV management who want an update

More information

Diagnosing HIV/AIDS. Marissa Humphrey MSIV New York Medical College GE/NMF Scholar

Diagnosing HIV/AIDS. Marissa Humphrey MSIV New York Medical College GE/NMF Scholar Diagnosing HIV/AIDS Marissa Humphrey MSIV New York Medical College GE/NMF Scholar Introduction The World Health Organization estimates that 7 percent of all AIDS cases have occurred in Africa and the highest

More information

Annex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)

Annex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms) IMPACT INDICATORS (INDICATORS PER GOAL) HIV/AIDS TUBERCULOSIS MALARIA Reduced HIV prevalence among sexually active population Reduced HIV prevalence in specific groups (sex workers, clients of sex workers,

More information

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /

More information

Can we make first line ART better?

Can we make first line ART better? Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics

More information

LOGFRAME TEMPLATE FOR SWAZILAND. SIDA s Contributions

LOGFRAME TEMPLATE FOR SWAZILAND. SIDA s Contributions 1 Outcome 7 countries have addressed barriers to efficient and effective linkages between HIV and SRHR policies and services as part of strengthening health systems to increase access to and use of a broad

More information

Treat All : From Policy to Action - What will it take?

Treat All : From Policy to Action - What will it take? Strategy Finance Integration Cascade of services People centred Political Will Treat All : From Policy to Action - What will it take? Thursday, 9 June, 13.00 14.30 Conference Room 11, United Nations Questions

More information

Impact of ART resistance in sub Saharan Africa

Impact of ART resistance in sub Saharan Africa Impact of ART resistance in sub Saharan Africa Elliot Raizes, MD Division of Global HIV/TB US Centers for Disease Control and Prevention ITREMA Resistance Training Workshop 24 October, 2018 Center for

More information

Achieving the 3 rd 90 in PEPFAR-supported countries:

Achieving the 3 rd 90 in PEPFAR-supported countries: Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention

More information

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for

More information

PRECONCEPTION COUNSELING

PRECONCEPTION COUNSELING PRECONCEPTION COUNSELING A Counseling Guide for Healthcare Providers Preconception Care & Counseling 1 Introduction Pregnancy planning and preconception care are important in order to: 1. Ensure maternal

More information

Technical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults

Technical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults Technical Guidance Note for Global Fund HIV Proposals TREATMENT - Antiretroviral Treatment-infants, children and adults May 2010 This technical brief is designed to provide key technical information to

More information

JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN

JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim

More information

CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries. The case against Di Gibb

CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries. The case against Di Gibb CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries The case against Di Gibb The value of CD4 Pre-ART CD4 CD4 monitoring on ART Pre-ART CD4 for linkage to care & clinical management

More information

The CQUIN Learning Network

The CQUIN Learning Network The CQUIN Learning Network Adolescents Living with HIV: Innovations and Experience Shenaaz Pahad Wits Reproductive Health and HIV Institute October 24-27, 2017 Johannesburg, South Africa Why adolescents

More information

HIV Clinical Management: Antiretroviral Therapy and Drug Resistance

HIV Clinical Management: Antiretroviral Therapy and Drug Resistance HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible

More information

HIV and AIDS Estimates

HIV and AIDS Estimates and AIDS Estimates Adults and children living with Adults aged 15 and over living with Women aged 15 and over living with Men aged 15 and over living with 200 000 [180 000-210 000] 190 000 [170 000-200

More information

Botswana Advocacy paper on Resource Mobilisation for HIV and AIDS

Botswana Advocacy paper on Resource Mobilisation for HIV and AIDS Republic of Botswana Botswana Advocacy paper on Resource Mobilisation for HIV and AIDS Page 1 June 2012 1.0 Background HIV and AIDS remains one of the critical human development challenges in Botswana.

More information

Botswana. HIV Country Profile: Health expenditure, total (% of GDP) (2016) Total fertility rate (births per woman) ( )

Botswana. HIV Country Profile: Health expenditure, total (% of GDP) (2016) Total fertility rate (births per woman) ( ) WHO/CDS/HIV/18.5 Demographic and socioeconomic data Botswana HIV Country Profile: 217 2.3 million Total population (217) 16 99 US$ GNI per capita, PPP (217) World Bank 129 Maternal mortality per 1 live

More information

Natural history of HIV Infection

Natural history of HIV Infection HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment

More information

HIV Epidemic in India

HIV Epidemic in India HIV Epidemic in India Dr.R.R.Gangakhedkar Head, Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research New Delhi Waves in Spread of HIV Epidemic Core Group Bridge Populationmostly

More information

ACHAP LESSONS LEARNED IN BOTSWANA KEY INITIATIVES

ACHAP LESSONS LEARNED IN BOTSWANA KEY INITIATIVES ACHAP Together with our company s foundation, a U.S.-based, private foundation, and the Bill & Melinda Gates Foundation, we established the African Comprehensive HIV/AIDS Partnerships (ACHAP) in 2000 to

More information

Objectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.

Objectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care. 1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships

More information

COMMUNITY SYSTEMS TOOLBOX COMMUNITY SYSTEMS STRENGTHENING. Increasing access to quality health and social services. Building strong communities.

COMMUNITY SYSTEMS TOOLBOX COMMUNITY SYSTEMS STRENGTHENING. Increasing access to quality health and social services. Building strong communities. #4 COMMUNITY SYSTEMS TOOLBOX COMMUNITY SYSTEMS STRENGTHENING Increasing access to quality health and social services. Building strong communities. Coordinated, capacitated and resilient communities play

More information

CLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016

CLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016 CLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016 MORNING PLENARY LECTURES: LIBERTY BALLROOM (M4) 9:00 9:15 AM Welcome and Introductions Conference Co-Chairs: Laura W. Cheever, MD, ScM; Michael S.

More information

Evidence-based ART adherence. Dr Catherine Orrell Desmond Tutu HIV Foundation 26 November 2012

Evidence-based ART adherence. Dr Catherine Orrell Desmond Tutu HIV Foundation 26 November 2012 Evidence-based ART adherence Dr Catherine Orrell Desmond Tutu HIV Foundation 26 November 2012 What is adherence? There are two main components: 1) Adherence to daily treatment All tablets taken At the

More information

Clinical Cases: Integrase Inhibitor use in Africa. Dr Julia Turner Medical Advisor Right to Care NGO

Clinical Cases: Integrase Inhibitor use in Africa. Dr Julia Turner Medical Advisor Right to Care NGO Clinical Cases: Integrase Inhibitor use in frica Dr Julia Turner Medical dvisor Right to Care NGO Disclosure Receipt of grants/ research supports Right to Care NGO is funded by USID PEPFR, ealth Systems

More information

The outlook for hundreds of thousands adolescents is bleak.

The outlook for hundreds of thousands adolescents is bleak. Adolescents & AIDS Dr. Chewe Luo Chief HIV/AIDS, UNICEF Associate Director, Programmes Division 28/11/17 Professor Father Micheal Kelly Annual Lecture on HIV/AIDS Dublin, Ireland The outlook for hundreds

More information

Overview of Safer Conception Services at Wits RHI

Overview of Safer Conception Services at Wits RHI SA AIDS Satellite Session 13 June 2017 Presented by Diantha Pillay on behalf of Dr. Natasha Davies, Sheree Swartz, Nicolette Naidoo & Saiqa Mullick Overview of Safer Conception Services at Wits RHI Safer

More information

Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV. Mon Mari Mon Visa : Men as Change Agents in Côte d Ivoire

Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV. Mon Mari Mon Visa : Men as Change Agents in Côte d Ivoire Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV Mon Mari Mon Visa : Men as Change Agents in Côte d Ivoire 1 Optimizing HIV Treatment Access for Pregnant and Breastfeeding Women

More information

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

South African Guidelines for the Safe Use of. Dr. Oscar Radebe South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &

More information

SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED?

SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED? SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED? ETHICAL, CLINICAL AND COMMUNITY CONSIDERATIONS Eric Goemaere, MD, DTMH, PHD Senior HIV/TB program adviser MSF South Africa We loved

More information

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision Updated version following MERG recommendations Context In light of country reports, regional workshops and comments received by a

More information

Sexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012

Sexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3

More information